Group newsletter: CCTG Connection

Archived Bulletins

October 16, 2019

Published: October 16, 2019
Category: Trials
Closed to Acrual: CCTG IND232

CCTG IND232 (NCT02788773) - A Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer has been closed to accrual after the completion of target accrual.

Read More

Published: October 16, 2019
Category: Group updates
Pharmacist Representative for the Lung Disease Site Committee

The Pharmacist Network is actively seeking a volunteer as Pharmacist Representative for the Lung Disease Site Committee.

The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials.  Please review terms of reference at: Pharmacist Representatives on Disease Site Committees

Read More

Published: October 16, 2019
Category: News

Erwin Wanderer is the CCTG Patient Representative on the Genito-Urinary Disease Site Committee and Executive Committees, he resides in Halifax, Nova Scotia and has been CCTG Patient Representative since 2015. Erwin says, "I believe that being involved in a clinical trial can sometimes give patients access to procedures and treatments that they may not have been part of their original options.

Read More

October 02, 2019

Published: October 02, 2019
Category: Trials

CCTG SC.24, A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases, has been closed to accrual after the completion of target accrual. Although the trial is closed accrual, treatment and follow up of patients will continue according to the protocol.

The purpose of this study is to find out if SBRT is better than CRT at controlling pain in the spine 3 months after receiving treatment.

Read More

Published: October 02, 2019
Category: Trials
 CCTG IND.225 trial

The CCTG IND.225 trial: A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
has been permanently closed/terminated.

Read More

Published: October 02, 2019
Category: News
The use of Complementary Medicines is Relatively High

The use of Complementary Medicines is Relatively High Among Patients in Phase III Cancer Trials

Read More

Published: October 02, 2019
Category: News

This past weekend at the European Society for Medical Oncology congress in Barcelona, Spain, there were many poster presentations by CCTG researchers.

Poster Discussion: CCTG IND 232 - Phase II Study of Durvalumab with or without Tremelimumab in Patients with mCRPC

Read More

Dr. McKenzie

Dr. McKenzie is a radiation oncologist with extensive experience in genitourinary oncology, neurooncology and palliative oncology. He currently works as a radiation oncologist at BC Cancer Vancouver. He also is the co-chair of the CCTG Supportive Care Committee. In this video, McKenzie addresses the wide variety of trials the Supportive Care Committee is involved with, as well as potential avenues for new trials that may extend beyond the jurisdiction of cancer research.

Read More